Skip to main content

Information Management Unit (UGI)

The Information Management Unit (UGI) provides support to the clinical departments and management of the Institut Bordet.

The UGI carries out 4 particular missions:

  • An epidemiology mission – by developing, managing and operating the hospital Cancer Register and by incorporating into it data from multidisciplinary oncological consultations. In so doing it contributes actively to the Belgian Cancer Register and makes the hospital Cancer Register available as a research support and care quality evaluation tool.
  • An analysis and reporting mission in relation to the Institut’s activities, in particular by developing and maintaining a data warehouse.
  • An oncological clinical research mission in terms of methodology and statistics (single-centre and multicentre research, centralised at the Institut Bordet and elsewhere).
  • A website maintenance mission for the Institut Bordet.

Research projects

The UGI collaborates on many research projects at the request of the Institut Bordet clinical departments and of multicentre groups. It also develops its own projects, including:
  

Project 1

Identification and recording of relapse events in the Cancer Register

Our team

Coordination
Marianne Paesmans, director (actuary)

The team
Lieveke Ameye, statistician
Sylvie Berckmans, data manager

Alain Barbason, analyst data warehouse
Laurent Dubreucq, data manager
Audrey Duinslaeger, data manager
Aline Kayumba, data manager
Laetitia Martins, data manager

Michel Moreau, epidemiologist
Bernard Schenk, data warehouse officer
Louise Vanderweerden, webmaster and secretariat

 Scientific publications

Reactive stroma and trastuzumab resistance in HER2-positive early breast cancer.

Authors : Sonnenblick A, Salmon-Divon M, Salgado R, Dvash E, Pondé N, Zahavi T, Salmon A, Loibl S, Denkert C, Joensuu H, Ameye L, Van den Eynden G, Kellokumpu-Lehtinen PL, Azaria A, Loi S, Michiels S, Richard F, Sotiriou C
Year : 2020
Journal : Int J Cancer

CTCs as a prognostic and predictive biomarker for stage II/III Colon Cancer: a companion study to the PePiTA trial.

Authors : Rothé F, Maetens M, Rouas G, Paesmans M, Van den Eynde M, Van Laethem JL, Vergauwe P, Deboever G, Bareche Y, Vandeputte C, Ignatiadis M, Hendlisz A
Year : 2019
Journal : BMC Cancer
Volume : 19
Pages : 304

PRODIGE 7 should be interpreted with caution.

Authors : Liberale G, Ameye L, Hendlisz A
Year : 2019
Journal : Acta Chir Belg
Volume : 119
Pages : 263-266

Personalised radioembolization improves outcomes in refractory intra-hepatic cholangiocarcinoma: a multicenter study.

Authors : Levillain H, Duran Derijckere I, Ameye L, Guiot T, Braat A, Meyer C, Vanderlinden B, Reynaert N, Hendlisz A, Lam M, Deroose CM, Ahmadzadehfar H, Flamen P
Year : 2019
Journal : Eur J Nucl Med Mol Imaging
Volume : 46
Pages : 2270-2279

Tumor infiltrating B-cells signal functional humoral immune responses in breast cancer.

Authors : Garaud S, Buisseret L, Solinas C, Gu-Trantien C, de Wind A, Van den Eynden G, Naveaux C, Lodewyckx JN, Boisson A, Duvillier H, Craciun L, Ameye L, Veys I, Paesmans M, Larsimont D, Piccart-Gebhart M, Willard-Gallo K
Year : 2019
Journal : JCI Insight
Volume : 5